Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis
Range Bound setup
Healthcare · Drug Manufacturers - Specialty & Generic
Wait for pullback to $12.09. Weak momentum — blocks BUY_NOW at $12.95. Engine's entry $12.09 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: Cencora, McKesson Drug Co., Cardinal Health, and CVS Health Corporation (71.0%); Leverage penalty (D/E 451.0): -1.5.
Amneal Pharmaceuticals is a diversified global biopharmaceutical company with three segments: Affordable Medicines (generics, injectables, biosimilars), Specialty (branded CNS/endocrine), and AvKARE (federal government and institutional distribution). The company operates... Read more
Wait for pullback to $12.09. Weak momentum — blocks BUY_NOW at $12.95. Engine's entry $12.09 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: Cencora, McKesson Drug Co., Cardinal Health, and CVS Health Corporation (71.0%); Leverage penalty (D/E 451.0): -1.5. Chart setup: RSI 56 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Score 5.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on earnings proximity 0d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerCencora, McKesson Drug Co., Cardinal Health, and CVS Health Corporation71%10-K Item 1A: 'Our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc. and CVS Health Corporation, accounted for approximately 71%... of total net sales of products for the years ended December 31, 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $12.09. Weak momentum — blocks BUY_NOW at $12.95. Engine's entry $12.09 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Customer: Cencora, McKesson Drug Co., Cardinal Health, and CVS Health Corporation (71.0%); Leverage penalty (D/E 451.0): -1.5. Chart setup: RSI 56 mid-range, Bollinger mid-band. Earnings in 0 days. Wait until post-earnings. Target $14.79 (+14.2%), stop $11.10 (−16.7%), Setup A.R:R 3.1:1. Score 5.7/10, moderate confidence.
Take-profit target: $14.79 (+19.1% upside). Target $14.79 (+14.2%), stop $11.10 (−16.7%), Setup A.R:R 3.1:1. Stop-loss: $11.10.
Concentration risk — Customer: Cencora, McKesson Drug Co., Cardinal Health, and CVS Health Corporation (71.0%); Leverage penalty (D/E 451.0): -1.5; Value-trap signals (2/5): High leverage (D/E 7.8), Material insider selling (14 sells, 0.15% of cap).
Amneal Pharmaceuticals, Inc. trades at a P/E of 58.2 (forward 10.8). TrendMatrix value score: 7.3/10. Verdict: Buy (Wait for Entry).
11 analysts cover AMRX with a consensus score of 4.1/5. Average price target: $17.
What does Amneal Pharmaceuticals, Inc. do?Amneal Pharmaceuticals is a diversified global biopharmaceutical company with three segments: Affordable Medicines...
Amneal Pharmaceuticals is a diversified global biopharmaceutical company with three segments: Affordable Medicines (generics, injectables, biosimilars), Specialty (branded CNS/endocrine), and AvKARE (federal government and institutional distribution). The company operates principally in the U.S., India, and Ireland with over 1,300 customers and a generics portfolio of more than 120 products. In 2025, a Warning Letter was issued to its Gujarat, India manufacturing facility.